BrainStorm (NASDAQ: BCLI) taps ex-FDA leader to steer NurOwn trial
Rhea-AI Filing Summary
BrainStorm Cell Therapeutics reports significant leadership and compensation changes. The board appointed director Peter Pitts as Executive Chairman and Chief Strategic Regulatory and Policy Officer, granting him stock options for 900,000 common shares; he will not receive base salary, cash bonus, or director compensation. One-fourth of this option vests on July 24, 2027, with the remainder vesting in equal monthly installments over the following three years.
Professor Jacob Frenkel resigned as chairman and director, will serve as an advisor under a consulting agreement, and received 100,000 restricted stock units vesting in two tranches through April 24, 2027, along with accelerated vesting and extended exercise periods for his options; his resignation was not due to any disagreement. Executive Vice President and Chief Medical Officer Ibrahim Dagher resigned and will consult for one year under an agreement that treats his service as continued employment for equity awards and, upon successful completion, fully vests his outstanding equity and extends option exercise periods. A company press release highlights Pitts’s role in leading the planned NurOwn Phase 3b ALS trial under an FDA Special Protocol Assessment.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Pitts stock option grant: 900,000 shares
Frenkel RSU award: 100,000 shares
Pitts option initial vesting date: July 24, 2027
+1 more
4 metrics
Pitts stock option grant
900,000 shares
Stock option to purchase common stock as Executive Chairman and Chief Strategic Regulatory and Policy Officer
Frenkel RSU award
100,000 shares
Restricted stock units granted in connection with consulting agreement after resignation as chairman and director
Pitts option initial vesting date
July 24, 2027
One-fourth of the Pitts stock option vests on this date
Dagher consulting term
one year
Duration of consulting agreement following resignation as Executive Vice President and Chief Medical Officer
Key Terms
Special Protocol Assessment, Orphan Drug designation, restricted stock units, autologous mesenchymal stem cells
4 terms
Special Protocol Assessment regulatory
"Phase 3b trial for NurOwn under an FDA Special Protocol Assessment"
A special protocol assessment is a formal, written agreement between a drug or device developer and a health regulator about the design, size and analysis plans of a pivotal clinical trial or study. It matters to investors because it reduces regulatory uncertainty—like getting a signed blueprint before building—by signaling that if the study follows the agreed plan and meets its goals, the regulator is unlikely to reject the results solely for design reasons, though it does not guarantee approval.
Orphan Drug designation regulatory
"NurOwn has received Orphan Drug designation from the FDA and EMA"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
restricted stock units financial
"award of restricted stock units covering 100,000 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
autologous mesenchymal stem cells medical
"NurOwn platform uses autologous mesenchymal stem cells to produce cells"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What leadership changes did BrainStorm Cell Therapeutics (BCLI) announce?
BrainStorm appointed Peter Pitts as Executive Chairman and Chief Strategic Regulatory and Policy Officer, while Professor Jacob Frenkel resigned as chairman and director to become Senior Advisor and Ibrahim Dagher resigned as Executive Vice President and Chief Medical Officer to serve as a consultant.
What are the key terms of Peter Pitts’s stock option grant at BCLI?
Peter Pitts received a stock option for 900,000 shares of common stock. One-fourth vests on July 24, 2027, with the remaining shares vesting in equal monthly installments over the next three years, and he will not receive salary, cash bonus, or director fees.
How is Professor Jacob Frenkel’s role and compensation changing at BrainStorm (BCLI)?
Professor Jacob Frenkel resigned as chairman and director and will serve as an advisor under a consulting agreement. He received 100,000 RSUs, vesting half on October 24, 2026 and half on April 24, 2027, plus accelerated equity vesting and extended option exercise periods.
What are the main terms of Ibrahim Dagher’s consulting agreement with BCLI?
After resigning as Executive Vice President and Chief Medical Officer, Ibrahim Dagher will consult for one year. During this term, service counts as continued employment for equity awards, which will fully vest at the end if he complies, with extended post-termination option exercise periods.
What is NurOwn and what regulatory status has it received according to BCLI?
NurOwn is BrainStorm’s lead investigational therapy for amyotrophic lateral sclerosis (ALS), based on autologous mesenchymal stem cells. It has received Orphan Drug designation from both the U.S. Food and Drug Administration and the European Medicines Agency, and completed a Phase 3 trial in ALS.
What is notable about the planned NurOwn Phase 3b trial mentioned by BCLI?
The planned Phase 3b NurOwn trial in ALS will proceed under an FDA Special Protocol Assessment. BrainStorm notes this is the first SPA ever granted for an ALS therapeutic candidate, and Executive Chairman Peter Pitts will lead the clinical-regulatory strategy for this study.